India's Gland Pharma posts higher quarterly profit on strong US, Europe demand

Gland Pharma

28/01/2026 12:38

Jan 28 (Reuters) - India's Gland Pharma GLAD.NS reported a nearly 28% jump in third-quarter profit on Wednesday, boosted by strong sales in the key European and U.S. markets.

The Hyderabad-based company reported a consolidated net profit of 2.61 billion rupees ($28.40 million) for the quarter ended December 31, from 2.05 billion rupees a year earlier.

Revenue from operations rose 22.5% to 16.95 billion rupees.

Its U.S. sales, which make up more than half of the total, rose 19%, while its Europe business posted a 54% rise.

For further results highlights, click nFWN3YT0JZ

KEY CONTEXT

Gland Pharma and several Indian drugmakers that produce generic medicines derive a large share of their revenue from the U.S.

The company reported double-digit sales growth in the U.S., while its larger rivals Cipla CIPL.NS and Dr. Reddy's REDY.NS  reported a decline due to intense competition during the period.

Gland Pharma's Cenexi unit in France and Belgium also recovered from a production disruption that had affected it through much of 2025.

Cenexi's strong revenue traction was a key contributor to the company's consolidated performance in the quarter, CEO Shyamakant Giri said.

Earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 21% in the quarter ended December compared to a year earlier.

PEER COMPARISON

Estimates (next 12 months)
Analysts' sentiment
RIC
PE
EV/EBITDA
Revenue growth (%)
Profit growth (%)
Mean rating*
# of analysts
Stock to price target**
Div yield (%)
Gland Pharma Ltd
GLAD.NS
23.83
13.53
13.99
28.59
Hold
14
0.84
1.07
Zydus Lifesciences Ltd
ZYDU.NS
21.25
14.31
7.27
-9.78
Hold
29
0.89
1.23
Dr Reddy's Laboratories Ltd
REDY.NS
21.61
13.06
3.37
-10.20
Hold
39
0.92
0.65
Cipla Ltd
CIPL.NS
23.33
14.92
7.73
0.21
Hold
37
0.90
0.99

* Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell

** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

OCTOBER TO DECEMBER STOCK PERFORMANCE

-- All data from LSEG

-- $1 = 91.8990 Indian rupees

GLAD v Peers https://tmsnrt.rs/45D6D2V

(Reporting by Kashish Tandon and Nishit Navin in Bengaluru; Editing by Harikrishnan Nair)

((Kashish.Tandon@thomsonreuters.com; 8800437922;))